Kura Oncology Income Statement (2024-2025) | KURA

Income Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue -0.40M-0.41M-0.41M-0.40M14.11M15.29M20.75M
Operating items
Research & Development 36.27M39.73M41.70M52.27M55.97M62.78M67.91M
Selling, General & Administrative 18.18M16.68M18.18M24.07M22.84M25.17M32.84M
Operating Expenses 54.45M56.40M59.88M76.34M78.81M87.95M100.75M
Operating Income -54.45M-56.40M-59.88M-22.45M-64.70M-72.67M-80.00M
EBIT -54.45M-56.40M-59.88M-22.45M-64.70M-72.67M-80.00M
Non-operating items
Interest & Investment Income 5.33M5.97M5.89M5.66M7.88M6.93M6.27M
Non Operating Income 4.93M5.57M5.48M5.26M7.50M6.54M5.88M
Net income details
EBT -49.52M-50.84M-54.40M-17.20M-57.20M-66.12M-74.12M
Tax Provisions 0.23M
Profit After Tax -49.52M-50.84M-54.40M-19.22M-57.43M-66.12M-74.12M
Income from Continuing Operations -49.52M-50.84M-54.40M-17.20M-57.43M-66.12M-74.12M
Consolidated Net Income -49.52M-50.84M-54.40M-17.20M-57.43M-66.12M-74.12M
Income towards Parent Company -49.52M-50.84M-54.40M-17.20M-57.43M-66.12M-74.12M
Net Income towards Common Stockholders -49.52M-50.84M-54.40M-17.20M-57.43M-66.12M-74.12M
Additional items
EPS (Basic) -0.59-0.59-0.63-0.22-0.66-0.75-0.85
EPS (Weighted Average and Diluted) -0.59-0.59-0.63-0.22-0.66-0.75-0.85
Shares Outstanding (Weighted Average) 76.14M76.18M76.63M77.76M80.75M86.57M86.80M
Shares Outstanding (Diluted Average) 83.91M86.64M86.95M86.16M87.42M87.59M87.64M
EBITDA -49.07M-50.48M-52.83M-19.57M-64.70M-72.67M-80.00M
Interest Expenses 0.40M0.41M0.41M0.40M0.38M0.39M0.39M
Shares Outstanding 76.18M76.42M77.75M78.23M80.78M86.80M87.02M